Free Trial

DocGo Inc. (NASDAQ:DCGO) Receives $4.89 Consensus Price Target from Analysts

DocGo logo with Medical background

DocGo Inc. (NASDAQ:DCGO - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $4.89.

DCGO has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft downgraded DocGo from a "buy" rating to a "hold" rating and reduced their price target for the company from $5.00 to $2.85 in a research note on Friday, February 28th. Needham & Company LLC restated a "buy" rating and issued a $4.00 price target on shares of DocGo in a research note on Tuesday, April 8th. Finally, Stifel Nicolaus dropped their price objective on shares of DocGo from $6.50 to $5.50 and set a "buy" rating for the company in a research note on Friday, February 28th.

Get Our Latest Research Report on DocGo

Institutional Investors Weigh In On DocGo

A number of large investors have recently bought and sold shares of the company. Summit Investment Advisors Inc. lifted its holdings in shares of DocGo by 38.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 10,639 shares of the company's stock worth $45,000 after acquiring an additional 2,968 shares during the period. Prudential Financial Inc. acquired a new stake in DocGo in the fourth quarter valued at about $55,000. Royce & Associates LP bought a new position in DocGo in the fourth quarter valued at about $64,000. Boothbay Fund Management LLC raised its stake in DocGo by 154.9% during the fourth quarter. Boothbay Fund Management LLC now owns 27,445 shares of the company's stock worth $116,000 after acquiring an additional 77,445 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of DocGo by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,641 shares of the company's stock worth $121,000 after acquiring an additional 9,425 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

DocGo Price Performance

DocGo stock traded down $0.02 during trading hours on Friday, hitting $2.15. The company had a trading volume of 119,284 shares, compared to its average volume of 746,359. The firm has a 50-day moving average of $3.03 and a 200 day moving average of $3.77. The firm has a market cap of $218.75 million, a PE ratio of 7.66, a PEG ratio of 14.16 and a beta of 1.12. DocGo has a one year low of $2.02 and a one year high of $5.68.

DocGo Company Profile

(Get Free Report

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.

Recommended Stories

Analyst Recommendations for DocGo (NASDAQ:DCGO)

Should You Invest $1,000 in DocGo Right Now?

Before you consider DocGo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocGo wasn't on the list.

While DocGo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Blowout Earnings Winners That Could Soar Even Higher
5 Stocks You’ve Never Heard Of That I’m Buying Nonstop in 2025
3 Sectors With Massive Momentum You Can’t Afford to Miss

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines